Learn Mode

TGTX - TG Therapeutics Inc

22

$33.46

$1.95 (6.189%)

3/31/26, 5:09 PM

Score

4.41/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

TGTX

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$5.22B

Industry

Biotechnology

EPS (TTM)

$2.80

P/E (TTM)

11.67

Div & Yield

FCF Payout Ratio

P/S (TTM)

8.47

P/B

8.05

Diluted Shares

159.34M

Ex-Dividend

Next Earnings

05-04

Forward P/E

21.94

Payout Ratio

P/FCF (TTM)

0.00

FCF Yield

Earnings Yield

8.57%

52 Week Range

Score Card

Explore Scores Tab

4.41

Very Good

TG Therapeutics Inc has grown revenue at 87.32% over the past year, which is strong growth. Also, it has seen its diluted average shares outstanding decrease by -0.56% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

3.00

Average

Management

3.00

Average

Growth

2.00

Bad

Profitability

3.00

Average

Fin. Health

5.00

Very Good

Dividends

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:34:09

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-20 16:33:42

Form 10-K

Annual financials report pursuant to Section 13 or 15(d)

Filed on 2026-02-27 17:05:11

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-02-26 07:08:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-01-29 17:24:42

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-01-13 16:27:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-01-09 17:16:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-01-09 17:15:33

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2025-11-25 17:31:57

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2025-11-24 16:04:15

Form SCHEDULE 13G

Unknown Form Type

Filed on 2025-11-10 08:58:45

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2025-11-07 17:01:49

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$63.00

88.3%

Avg:

$45.05

34.6%

Low:

$15.15

-54.7%

(% change is relative to the current stock price: $33.46)

Analyst Recommendations

Go to Analyst Tab

3.93

Good

20%

Strong Buy (3)

60%

Buy (9)

13%

Hold (2)

Sell (1)

Strong Sell (0)

About

Website
https://www.tgtherapeutics.com/
Address
3020 Carrington Mill Blvd., Suite 475, Morrisville NORTH CAROLINA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1001316

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

IPO Date

1995-12-14

Industry

Biotechnology

Total Employees

399

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

TGTX - TG Therapeutics Inc

22

$33.46

$1.95 (6.189%)

4.41/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-03-27 13:34:09

Form 8-K

Filed on 2026-03-20 16:33:42

Form 10-K

Filed on 2026-02-27 17:05:11

Form 8-K

Filed on 2026-02-26 07:08:34

Form 4

Filed on 2026-01-29 17:24:42

Form 8-K

Filed on 2026-01-13 16:27:48

Form 4

Filed on 2026-01-09 17:16:39

Form 4

Filed on 2026-01-09 17:15:33

Form 4

Filed on 2025-11-25 17:31:57

Form 144

Filed on 2025-11-24 16:04:15

Form SCHEDULE 13G

Filed on 2025-11-10 08:58:45

Form 4

Filed on 2025-11-07 17:01:49

Financials

Price Targets

88.3%

34.6%

-54.7%

Analyst Recommendations

About

Similar Stocks